Meeting Overview - The second meeting of the Supervisory Board of Jiangsu Yahon Pharmaceutical Technology Co., Ltd. was held on June 20, 2025, with full attendance of all three supervisors [1]. Resolutions Passed - The Supervisory Board approved the proposal to annul part of the restricted stock from the 2022 incentive plan that had been granted but not yet vested, confirming compliance with relevant laws and regulations [1][2]. - The Board also approved the conditions for the second vesting period of the initial grant and the first vesting period of the reserved grant under the 2022 incentive plan, stating that the conditions had been met [2][3]. - The company agreed to provide guarantees for its wholly-owned subsidiaries, Shanghai Yahon Pharmaceutical Technology Co., Ltd. and Hainan Yahon Pharmaceutical Trading Co., Ltd., for a total bank credit limit not exceeding RMB 150 million, which represents 7.62% of the company's latest audited net assets [3].

Core Viewpoint - The company has provided a guarantee of 600 million RMB for its subsidiaries to secure bank credit facilities, which is expected to support their operational needs and promote sustainable development [1][4]. Summary by Sections Guarantee Overview - The total guarantee amount provided by the company for its subsidiaries is 60,000 million RMB [1]. - The guarantee is a joint liability guarantee without any counter-guarantee [1]. - There are no overdue guarantees reported [1]. Subsidiary Information - The subsidiaries involved in the guarantee include: - Xinjiang Kangzhiyuan Pharmaceutical Co., Ltd. with a guarantee of 6,000 million RMB [1]. - Yili Kangzhiyuan Pharmaceutical Chain Co., Ltd. with a guarantee of 6,000 million RMB [1]. - Luoyang Dacarelin Pharmaceutical Co., Ltd. with a guarantee of 5,000 million RMB [1]. - Yingkou Fujuhe Pharmaceutical Chain Co., Ltd. with a guarantee of 3,000 million RMB [1]. - Xuchang Dacarelin Baoyuantang Pharmacy Chain Co., Ltd. with a guarantee of 2,000 million RMB [1]. - Maoming Dacarelin Chain Pharmacy Co., Ltd. with a guarantee of 27,000 million RMB [1]. - Xinyang Dacarelin Baixingfu Pharmaceutical Chain Co., Ltd. with a guarantee of 6,000 million RMB [1]. Financial Health of Subsidiaries - The subsidiaries have shown stable financial conditions, with total assets and liabilities as follows: - Xinjiang Kangzhiyuan: Total assets of 223.76 million RMB, liabilities of 200.03 million RMB, and net profit of 4.60 million RMB [2]. - Yili Kangzhiyuan: Total assets of 223.25 million RMB, liabilities of 175.11 million RMB, and net profit of 4.91 million RMB [2]. - Luoyang Dacarelin: Total assets of 408.73 million RMB, liabilities of 257.37 million RMB, and net profit of 14.47 million RMB [2]. - Yingkou Fujuhe: Total assets of 78.20 million RMB, liabilities of 49.33 million RMB, and net profit of 1.13 million RMB [2]. - Xuchang Dacarelin: Total assets of 90.55 million RMB, liabilities of 67.47 million RMB, and net profit of 1.37 million RMB [2]. - Maoming Dacarelin: Total assets of 1,992.40 million RMB, liabilities of 1,167.19 million RMB, and net profit of 131.63 million RMB [2]. - Xinyang Dacarelin: Total assets of 87.87 million RMB, liabilities of 45.28 million RMB, and net profit of 1.02 million RMB [2]. Necessity and Reasonableness of Guarantee - The guarantee is deemed necessary to meet the operational needs of the subsidiaries and aligns with the company's overall interests and development strategy [4]. - The subsidiaries are reported to have stable financial conditions and good creditworthiness, indicating their ability to repay the debts [4]. Cumulative External Guarantee - As of the announcement date, the total amount of guarantees signed after the 2024 annual general meeting authorization is 600 million RMB, accounting for 6.95% of the company's latest audited net assets [5]. - There are no overdue external guarantees or guarantees involving litigation reported [5].

Group 1: Comprehensive Credit Facility Application - The company plans to apply for a comprehensive credit facility of up to RMB 1,199,200 million for the year 2025 to meet daily operational needs and maintain cash flow stability [1][2] - The credit facility will be used for various financing needs including short-term loans, medium to long-term borrowings, bank acceptance bills, guarantees, letters of credit, mortgage loans, and leasing [1] - The facility is authorized to be used cyclically within the approved limit from the date of approval by the 2024 annual general meeting until December 31, 2025 [1] Group 2: Guarantees for Subsidiaries - The company has approved a guarantee amount not exceeding RMB 1,172,720 million for its subsidiaries for the year 2025 to support their operational development [6][24] - The guarantee will be effective from the date of approval by the 2024 annual general meeting until December 31, 2025, with the authority granted to the chairman or authorized representatives to execute necessary documents [6] - The board believes that this guarantee will facilitate the sustainable and stable development of the subsidiaries and align with the overall strategic goals of the company [24] Group 3: Accounting Policy Change - The company has changed its accounting policy in accordance with the Ministry of Finance's regulations, which will take effect from January 1, 2024 [27][31] - The change is based on the new guidelines regarding the classification of current and non-current liabilities, supplier financing arrangements, and accounting treatment for sale-leaseback transactions [27] - The company asserts that this change will not have a significant impact on its financial position, operating results, or cash flow [31]